Information on how to access Mylotarg™▼ (gemtuzumab ozogamicin) and cytarabine prescribing information and adverse event reporting can be found at the bottom of the page.
To support your patient through their AML journey with MYLOTARG, there is a patient booklet as well as the Patient Information Leaflet (PIL). These are available to download or alternatively hard copies can be ordered through the Medisa site. See link to the right of this page
Download the MYLOTARG patient booklet to provide more information on MYLOTARG to your patients
Download Patient Booklet
Download the MYLOTARG patient information leaflet that is also available in the pack that holds the regulatory approved information for MYLOTARG patients
Patient Information Leaflet
AML, Acute Myeloid Leukaemia
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020